Ireland· IE-PA-EU/1/11/749/002
Caprelsa 300 mg film-coated tablets
A vandetanib product containing vandetanib, registered in Ireland by Esteve Pharmaceuticals S.A..
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Vandetanib
- Manufacturer
- Esteve Pharmaceuticals S.A.
- Country
- Ireland (IE)
- ATC code
- L01XE12
- ATC class
- Vandetanib
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/11/749/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
351 interactions on record for vandetanib.
Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vandetanib · interactions on record
351 records
- 244 severe
- 95 moderate
- 12 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vandetanib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCaprelsa 300 mgEsteve Pharmaceuticals
- CzechiaCAPRELSAEsteve Pharmaceuticals S.A., Barcelona
- SpainCAPRELSA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAEsteve Pharmaceuticals S.A.
- FinlandCaprelsaEsteve Pharmaceuticals S.A.S.
- FranceCAPRELSA 300 mg, comprimé pelliculéESTEVE PHARMACEUTICALS (ESPAGNE)
- IcelandCaprelsaEsteve Pharmaceuticals S.A.
- NetherlandsCaprelsa, 300 mg filmomhulde tablettenEsteve Pharmaceuticals S.A.
- NorwayCaprelsaEsteve Pharmaceuticals S.A
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Caprelsa
- Liechtenstein · Caprelsa
- Norway · Caprelsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4115c54-4178-4a0a-8728-abd4d9612c9e GET /v1/drugs/f4115c54-4178-4a0a-8728-abd4d9612c9e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01XE",
"L01XE12"
],
"strength": null,
"pa_number": "EU/1/11/749/002",
"substances": [
"Vandetanib"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about vandetanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.